Kidney Cancer – Pipeline Review, H1 2012
Kidney Cancer – Pipeline Review, H1 2012
Reference Code: GMDHC1632IDB
Publication Date: January 2012
Kidney Cancer – Pipeline Review, H1 2012 GMDHC1632IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Kidney Cancer – Pipeline Review, H1 2012
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables ............................................................................................................................................................................... 10
List of Figures .............................................................................................................................................................................. 14
Introduction....................................................................................................................................................................................... 15
Global Markets Direct Report Coverage ...................................................................................................................................... 15
Kidney Cancer Overview .................................................................................................................................................................. 16
Therapeutics Development............................................................................................................................................................... 17
An Overview of Pipeline Products for Kidney Cancer .................................................................................................................. 17
Kidney Cancer Therapeutics under Development by Companies .................................................................................................... 19
Kidney Cancer Therapeutics under Investigation by Universities/Institutes...................................................................................... 27
Late Stage Products ......................................................................................................................................................................... 39
Comparative Analysis .................................................................................................................................................................. 39
Mid Clinical Stage Products.............................................................................................................................................................. 40
Comparative Analysis .................................................................................................................................................................. 40
Early Clinical Stage Products ........................................................................................................................................................... 41
Comparative Analysis .................................................................................................................................................................. 41
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 42
Comparative Analysis .................................................................................................................................................................. 42
Kidney Cancer Therapeutics – Products under Development by Companies .................................................................................. 43
Kidney Cancer Therapeutics – Products under Investigation by Universities/Institutes ................................................................... 52
Companies Involved in Kidney Cancer Therapeutics Development ................................................................................................. 79
Bristol-Myers Squibb Company ................................................................................................................................................... 79
Genzyme Corporation ................................................................................................................................................................. 80
Boehringer Ingelheim GmbH ....................................................................................................................................................... 81
F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 82
Kyowa Hakko Kirin Co., Ltd. ........................................................................................................................................................ 83
Amgen Inc. .................................................................................................................................................................................. 84
AstraZeneca PLC ........................................................................................................................................................................ 85
Eli Lilly and Company .................................................................................................................................................................. 86
GlaxoSmithKline plc .................................................................................................................................................................... 87
Seattle Genetics, Inc. .................................................................................................................................................................. 88
Genentech, Inc. ........................................................................................................................................................................... 89
Merck & Co., Inc. ......................................................................................................................................................................... 90
Emergent BioSolutions Inc. ......................................................................................................................................................... 91
Oxford BioMedica plc .................................................................................................................................................................. 92
Light Sciences Oncology, Inc. ..................................................................................................................................................... 93
Novartis AG ................................................................................................................................................................................. 94
ImClone Systems Incorporated ................................................................................................................................................... 95
Astellas Pharma Inc..................................................................................................................................................................... 96
Eisai Co., Ltd. .............................................................................................................................................................................. 97
Ono Pharmaceutical Co., Ltd....................................................................................................................................................... 98
OSI Pharmaceuticals, Inc. ........................................................................................................................................................... 99
Kidney Cancer – Pipeline Review, H1 2012 GMDHC1632IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Kidney Cancer – Pipeline Review, H1 2012
Pfizer Inc.................................................................................................................................................................................... 100
Taiho Pharmaceutical Co., Ltd. ................................................................................................................................................. 101
Exelixis, Inc................................................................................................................................................................................ 102
Alfacell Corporation ................................................................................................................................................................... 103
Celgene Corporation ................................................................................................................................................................. 104
Bayer AG ................................................................................................................................................................................... 105
MannKind Corporation............................................................................................................................................................... 106
3SBio Inc. .................................................................................................................................................................................. 107
EntreMed, Inc. ........................................................................................................................................................................... 108
Celldex Therapeutics, Inc. ......................................................................................................................................................... 109
Active Biotech AB ...................................................................................................................................................................... 110
AEterna Zentaris Inc. ................................................................................................................................................................. 111
AIDA Pharmaceuticals, Inc. ....................................................................................................................................................... 112
Lorus Therapeutics Inc .............................................................................................................................................................. 113
Bionomics Limited ..................................................................................................................................................................... 114
Northwest Biotherapeutics, Inc. ................................................................................................................................................. 115
Cleveland BioLabs, Inc. ............................................................................................................................................................. 116
Patrys Limited ............................................................................................................................................................................ 117
Keryx Biopharmaceuticals, Inc. ................................................................................................................................................. 118
ARQULE, INC............................................................................................................................................................................ 119
Allos Therapeutics, Inc .............................................................................................................................................................. 120
Flamel Technologies S.A........................................................................................................................................................... 121
Dendreon Corporation ............................................................................................................................................................... 122
Green Cross Corporation .......................................................................................................................................................... 123
MOLOGEN AG .......................................................................................................................................................................... 124
OncoTherapy Science, Inc. ....................................................................................................................................................... 125
Threshold Pharmaceuticals, Inc. ............................................................................................................................................... 126
Innate Pharma SA ..................................................................................................................................................................... 127
Protox Therapeutics Inc............................................................................................................................................................. 128
Rexahn Pharmaceuticals, Inc. ................................................................................................................................................... 129
Debiopharm Group .................................................................................................................................................................... 130
Antisense Pharma GmbH .......................................................................................................................................................... 131
Wilex AG ................................................................................................................................................................................... 132
Philogen S.p.A. .......................................................................................................................................................................... 133
Cadila Pharmaceuticals Ltd. ...................................................................................................................................................... 134
ERYtech Pharma ....................................................................................................................................................................... 135
immatics biotechnologies GmbH ............................................................................................................................................... 136
Curacyte AG .............................................................................................................................................................................. 137
Argos Therapeutics, Inc............................................................................................................................................................. 138
Cytheris SA................................................................................................................................................................................ 139
Altor BioScience Corporation..................................................................................................................................................... 140
AgrenVec, S.L. .......................................................................................................................................................................... 141
Alethia Biotherapeutics Inc. ....................................................................................................................................................... 142
Gene Signal International SA. ................................................................................................................................................... 143
Kidney Cancer – Pipeline Review, H1 2012 GMDHC1632IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Kidney Cancer – Pipeline Review, H1 2012
MacroGenics, Inc....................................................................................................................................................................... 144
Pivotal BioSciences, Inc. ........................................................................................................................................................... 145
Neotropix, Inc. ........................................................................................................................................................................... 146
Jennerex Biotherapeutics, Inc. .................................................................................................................................................. 147
Endocyte, Inc. ............................................................................................................................................................................ 148
Advenchen Laboratories, LLC ................................................................................................................................................... 149
Immutep S.A. ............................................................................................................................................................................. 150
Syndax Pharmaceuticals, Inc. ................................................................................................................................................... 151
Esperance Pharmaceuticals, Inc. .............................................................................................................................................. 152
Welichem Biotech Inc. ............................................................................................................................................................... 153
Tigris Pharmaceuticals, Inc........................................................................................................................................................ 154
AVEO Pharmaceuticals, Inc. ..................................................................................................................................................... 155
KAHR medical Ltd. .................................................................................................................................................................... 156
Advanced Cancer Therapeutics ................................................................................................................................................ 157
Medical Enzymes AG ................................................................................................................................................................ 158
IkerChem S.L............................................................................................................................................................................. 159
Immunovative Therapies, Ltd. ................................................................................................................................................... 160
Kidney Cancer – Therapeutics Assessment ................................................................................................................................... 161
Assessment by Monotherapy Products ..................................................................................................................................... 161
Assessment by Combination Products ...................................................................................................................................... 162
Assessment by Route of Administration .................................................................................................................................... 163
Assessment by Molecule Type .................................................................................................................................................. 166
Drug Profiles................................................................................................................................................................................... 169
Nexavar - Drug Profile ............................................................................................................................................................... 169
Product Description............................................................................................................................................................... 169
Mechanism of Action ............................................................................................................................................................. 169
R&D Progress ....................................................................................................................................................................... 169
Axitinib - Drug Profile ................................................................................................................................................................. 171
Product Description............................................................................................................................................................... 171
Mechanism of Action ............................................................................................................................................................. 171
R&D Progress ....................................................................................................................................................................... 171
Axitinib - Drug Profile ..............